Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Feb 25;126(12):1795–1805. doi: 10.1038/s41416-022-01744-3

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 3 — Cathepsin F (CTSF) (a), Fibulin-1 (FBLN1) (b) and Aldo-keto reductase family 1 member B10 (AKR1B10) (c) representative immunohistochemistry (IHC) staining of paired primary lung tumour and brain metastasis (BM) tissues from 2 patients in cohort 3. A representative area is selected. Relative expressions of CTSF (d), FBLN1 (e) and AKR1B10 (f) in primary lung tumour and BM tissues of 10 patients are shown. 0: negative, 1: weak positive, 2: positive, 3: strong positive. Representative IHC staining for CTSF (g), FBLN1 (h) and AKR1B10 (i) of patients from each control in cohort 3. Corresponding non-tumour is matched with non-small cell lung cancer patient without BM.